

This article was downloaded by:

On: 24 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Liquid Chromatography & Related Technologies

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597273>

HPLC Analysis of Antiepileptic Drugs in Blood Samples: Microbore Separation of Fourteen Compounds

Uwe Juergens^a

^a Department of Biochemistry, Gesellschaft fuer Epilepsieforschung, Federal Republic of Germany

To cite this Article Juergens, Uwe(1987) 'HPLC Analysis of Antiepileptic Drugs in Blood Samples: Microbore Separation of Fourteen Compounds', *Journal of Liquid Chromatography & Related Technologies*, 10: 2, 507 — 532

To link to this Article: DOI: 10.1080/01483918708066732

URL: <http://dx.doi.org/10.1080/01483918708066732>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

HPLC ANALYSIS OF ANTIEPILEPTIC DRUGS IN BLOOD SAMPLES: MICROBORE SEPARATION OF FOURTEEN COMPOUNDS

Uwe Juergens

*Department of Biochemistry
Gesellschaft fuer Epilepsieforschung
Bethel Maraweg 13
D-4800 Bielefeld 13
Federal Republic of Germany*

I REVIEW OF HPLC METHODS FOR ANTIEPILEPTIC DRUG ANALYSES

A. INTRODUCTION

The regular drug monitoring of antiepileptic drugs (AEDs) in the blood of patients has become, for nearly ten years now, an integral part of treatment in the Epilepsy Centre "Bethel". In the last year (1985) ca. 15,000 blood samples containing AEDs were analysed in our laboratory. Only a few patients in Bethel (ca. 10%) are on monotherapy. About 20% of the patients take 2 AEDs, about 40% take 3 AEDs, and about 30% are on polytherapy with 4 or more AEDs.

Six AEDs, which Soldin [1] refers to as the principal antiepileptic agents, namely phenytoin (PT), phenobarbital

(PB), primidone (PR), carbamazepine (CBZ), ethosuximide (ET), and valproic acid (VPA) are the main drugs prescribed in Bethel. Apart from these there are still a number of patients who receive methsuximide, which is almost completely metabolised in the liver to its demethylated form, N-desmethylnmethsuximide (DM) [106].

Furthermore the serum concentrations of the clinically relevant metabolites (MBs) of PR, 2-ethyl-2-phenyl-malonediamide (PEMA), and of CBZ, carbamazepine-10,11-epoxide (EPO) and 10,11-dihydro-10,11-dihydroxy carbamazepine (DIOL) are routinely determined in our laboratory.

We have reprints of 104 publications (76 original papers and 28 short communications) which describe the high-performance liquid chromatographic (HPLC) analysis of the 6 main AEDs (PT, PB, PR, CBZ, ET, and VPA) in blood, plasma, or serum [2-105]. Papers about comparisons of methods and those about clinical applications which refer to methods already published are not included.

The HPLC determination of VPA is normally carried out separately from the determination of the remaining AEDs because its slight UV absorption makes derivatization necessary [25,31,32,56,58,70,71,76,85]. A simultaneous determination of VPA and four other AEDs is described in a paper which has just recently been published [103]. VPA is thereby eluted between PB and PT. The sensitivity of the detector is temporarily increased from 0.04 to 0.005 a.u.f.s. (absorbance unit full scale). For routine analyses it would be necessary that the detector is switched

automatically by a time controller. In our laboratory, the determination of VPA is carried out by a gas chromatographic (GC) method [107] because the sample pretreatment is faster using this GC method than using an HPLC method with a derivatisation step.

As a minimal requirement, in our opinion, a paper giving a routine method for the analysis of AEDs by HPLC (VPA papers excluded) should describe the simultaneous determination of the 5 common AEDs mentioned above (PT, PB, PR, CBZ, and ET). This minimal requirement is, however, fulfilled in only 36 of our reprints [12-14,16,18,26,27,35,38,39,44-48,52-54,59,62,64,66-68,72,77,79,82,86,87,89,91,93,95,97,104]. Many publications only describe the analytical procedure of a single AED. This applies especially to CBZ which is frequently the only drug, mostly together with its main metabolite EPO, determined. In the remaining publications the determinations of only 1-4 of the 5 AEDs, mentioned above, are described. These AEDs are sometimes determined together with substances which are not antiepileptic agents.

B. SAMPLE PRETREATMENT

The various methods for sample processing in the HPLC analyses of drugs in blood, plasma or serum samples can be divided into three basic procedures:

- 1) Protein precipitation using a solvent which is miscible with water.
- 2) Liquid-liquid extraction with a solvent which is immiscible with water.

- 3) Adsorption onto a solid material from which the drugs can be eluted after cleaning the sample.

Silica gel columns were exclusively used in chromatographic separations of AEDs, as described in the earlier papers (from 1973 to 1976). The sample pretreatment in these papers were according to procedure 2 (extraction with phase separation).

Only after the introduction of the reversed phase columns (from 1976 on) protein precipitation was made possible as the single step in the processing of the samples. In the papers with sample pretreatment according to the basic procedure 1 the acetonitrile precipitation of proteins is the favorite first step (about a quarter of all papers).

Liquid/liquid extraction of the samples including a phase separation from the water layer did not, however, lose its significance. The advantage of protein precipitation is the speed of operation, but its disadvantage is, however, that all water soluble impurities of the samples are injected together with the extracted drugs onto the column. On the contrary the chromatographic separations following liquid/liquid extraction are almost free of sample background.

A liquid/liquid extraction was carried out in about the half of the papers cited above. In these a chlorinated solvent was used most frequently (24 papers), although there are two disadvantages in its use. First chlorinated solvents show the highest partition coefficient espe-

cially for CBZ, but not for the other AEDs [108]. Secondly the organic solution is in the lower phase after centrifuging.

Extraction with diethyl ether or with solvent mixtures come next in the order of frequency of use. Surprisingly enough, only 4 papers had been published up until 1983 which mentioned the use of ethyl acetate as an extraction agent [38,39,53,61], although Meijer [108] showed, as early as 1975, that just this solvent is especially suitable for the simultaneous extraction of relatively polar and non-polar AEDs.

From 1982 to 1983 we compared the three basic procedures for sample pretreatment for the HPLC determination of AEDs in serum analysing more than 2,000 patient samples. From the results we decided, for technological and economical reasons, to use ethyl acetate extraction for the routine analytical processing of AED samples in our laboratory [109]. Ethyl acetate has in the last two years also been used by some other laboratories for the extraction of AEDs from serum or plasma samples [86,88,95,97,105].

The adsorption of the drugs onto a solid material has been quoted as basic procedure 3 of the sample processing methods for AED analysis. After separation from the sample matrix the AEDs are then again eluted from the adsorbent by an appropriate solvent. Ever since the mid-70s activated charcoal was used for this purpose [12,13,69,73].

A fully automated method was described in 1979 in which "an activated, sized divinylbenzene cross-linked polystyrene resin which acts as a lipophilic sorbant" was used [41]. Unfortunately this procedure did not include the determination of ET.

The first use of reversed phase (RP) silica gel as sorbent for AEDs from serum (SEP-PAK(R) cartridges) was described in 1981 [66]. The next off-line procedure using RP material (BOND ELUTE(R) tubes) for sample pretreatment was described by Kabra et al.[82] in 1983.

A fully automated column switching system using pre-columns filled with RP material for an on-line cleaning of biological samples was described in 1981 [110]. Following on this publication, the column switching method appeared to us to be also suitable for the determination of AEDs in serum samples. We described in 1983 the principle abilities of such a system for the analysis of AEDs in a preliminary study [77]. At first, we included protein precipitation with acetonitrile followed by a dilution of the solution with buffer because a major problem with serum direct injection was the blockage of the pre-columns.

A method for the direct injection of untreated serum samples was submitted by us in October 1983 for publication [89]. In February 1984 Nazareth et al.[90] likewise submitted a paper on the same subject. ET was, however, not determined in this paper. At the same time a further paper dealing with the AED determination by column switching with serum direct injection was published by Kuhnz et al.[91].

TABLE 1

Distribution of Sample Pretreatment Techniques in the Determination of AEDs in Blood Samples

Procedure 1		Procedure 2		Procedure 3	
Aceto-nitrile	28	Dichloromethane Chloroform	24	Reversed phase silica gel	5
Acetone	3	Solvent mixtures	12	Activated charcoal	4
Methanol Ethanol	2	Methylbutyl ether Diethyl ether	11	Kieselguhr	1
Perchloric acid	1	Ethyl acetate	9	Divinyl- benzene	1
		Petroleum ether Pentane	2		

In paper [3] direct injection of plasma samples onto an ion exchange column was made

The use of kieselguhr for the adsorption of AEDs from biological samples [28,109] is a technique which is a hybrid between procedure 2 and 3. First of all the aqueous sample is adsorbed onto the kieselguhr, but the following elution by a solvent which is not miscible with water is a liquid/liquid extraction between the organic solvent and the bound aqueous phase. In respect of the technical processing in the laboratory the use of kieselguhr should, however, be classed with the third basic procedure of sample pretreatment (adsorption on solid material).

C. LIQUID CHROMATOGRAPHIC CONDITIONS

With two exceptions, in which ion exchange columns were used [3,8], silica gel columns were used in the

methods first published for the analysis of AEDs in blood samples by HPLC. From 1976 on silica gel columns were nearly entirely replaced by columns of the reversed phase type. Two of the advantages of this column material are that the separation is independent of the water content of the sample and that a gradient elution is possible.

The gradient elution was, however, for a long time not used at all and even after 1982 only sparingly [77,86, 89,97,102,104], although modern HPLC systems are able to produce gradient profiles with excellent reproducibility. Gradient elutions shorten the separation times and enhance the sensitivity of detection of those substances which are eluted later on (especially PT and CBZ).

Some of the columns used for chromatographic analyses had in the first papers lengths of 25 cm [10,11,13] and internal diameters of 2 mm [4,5] or 9 mm [3]. Soon, however, two standard sizes were used, namely 25 cm x 4.6 mm and 30 cm x 3.9 mm. The latter size applies to the "µ-Bondapak"(R) column, which was until recently the most frequently used RP column.

In the first years of AED analyses by HPLC the columns were filled with a material with a particle size of 10 µm, or greater. The first separations using a material with a diameter of 5 µm were described in 1978 [24,28]. Due to a reduction in the particle size of the packing materials the separation efficiency of the columns was increased. Consequently, there is a tendency to reduce the length of the columns and consequently the time for a chromatographic run.

Hitherto only two reports of really genuine "high-speed" separations of AEDs (elution of the substances within 2 min) have, however, been published [73,82]. For these applications relatively short (10 cm) columns were filled with 3 μm packing materials. "High-speed" separations were achieved by using a relatively high flow rate of 3 ml/min. We tested the chromatographic conditions of Kabra et al.[82] but did not find sufficient resolution of PE, ET and PR as well as of DM and EPO.

Another direction of HPLC development has been a saving of eluents and an increase of sensitivity by reducing the internal diameter (I.D.) of the columns. A few of the earlier papers describe the use of silica gel columns with 2.0-2.1 mm I.D. [2,4,5,8,10]. The flow rates, in some of these papers, were also relatively low [3,5,8]. But the separations were not comparable with today's "microbore" HPLC because the HPLC equipment was so constructed that a considerable band spreading occurred. Only the modern generation of HPLC systems enable the advantages of microbore columns to be used.

II DETERMINATION OF ANTIEPILEPTIC DRUGS BY MICROBORE HPLC

A. INTRODUCTION

One of the main advantages of the modern microbore technique in HPLC is a saving in expensive solvents. As more than 15,000 patient samples are analysed in our

laboratory per year, we have partly switched over to microbore HPLC in the routine determination of AED concentrations in serum samples. The prerequisite for this was the installation of an HPLC system which in respect of the injector, capillaries, and the detector complies with the requirements of microbore HPLC (see Materials).

In 1984 our laboratory was commissioned by the firm Parke Davis & Co. (U.S.A.) to measure serum concentrations of the new antiepileptic drug "Zonisamide" (CI-912 or AD-810) for a European study. The samples were taken from patients suffering from complex focal seizures. Former studies with zonisamide (ZA) were carried out in Japan and in the U.S.A. with patients on ZA mono-medication. Consequently, the HPLC determinations of ZA in the blood samples could be carried out isocratically with short separation times [111,112].

The patients in the European study (which is still in progress) normally take in addition to ZA some of the 6 common AEDs mentioned in the first part, namely PT, PB, PR, CBZ, ET, and VPA. Apart from these some patients take further AEDs, namely oxcarbazepine [88,97,104,105,113-115] and mephenytoin [13,26,27,86,97,104,116]. Only trace concentrations of oxcarbazepine (OXC) were found in the blood of patients because it is nearly completely metabolised to 10,11-dihydro-10-hydroxy carbamazepine (OHC) and DIOL [113, 114]. The same applies to mephenytoin (MEPT) which is almost entirely demethylated to nirvanol (NIR) [116].

The isocratic conditions for the determination of ZA, described in [111,112], were not suitable for our purposes because CBZ (with an elution time of ca. 22 min) would interfere with ZA in the following chromatograms. Consequently, we had to develop new chromatographic conditions, using at first a conventional HPLC column (length 12.5 cm plus 4 cm guard column) filled with an ODS silica gel with a particle size of 5 μm . Using these conditions ZA, PT, PB, PR, CBZ, ET, and DM, as well as the metabolites PEMA, EPO and DIOL could be simultaneously analysed, without disturbing the separation by OXC, OHC, MEPT, or NIR [117].

The conditions for extraction were the same as those for our hitherto routine analyses of AEDs [109]. In the last year we then developed a base line separation of all 14 of the above mentioned compounds using a microbore column (20 cm x 2.1 mm).

B. MATERIALS and METHODS

Apparatus

Equipment was obtained from the following firms: automatic pipetter/diluter from Corning/Gilford, Duesseldorf (F.R.G); Rotixa/K centrifuge from Hettich, Tuttlingen (F.R.G); vortex mixer/evaporator from Buchler Instruments, Searle Analytic Inc., Fort Lee, NJ (U.S.A); HPLC 1090 and analytical column (20.0 cm x 2.1 mm I.D.) filled with Shandon Hypersil(R) ODS (particle size 5 μm) from Hewlett /Packard, Boeblingen (F.R.G). Rheodyne HPLC column inlet filters with exchangeable frits (1.5 mm diam., 0.5 μm pore size) from ERC GmbH, Alteglofsheim (F.R.G.).

Reagents

Acetonitrile ChromAR(R) was obtained from Promochem, Wesel (F.R.G) and water for HPLC from Baker Chemicals, Deventer (The Netherlands). All other chemicals were of analytical reagent-grade and obtained from Merck, Darmstadt (F.R.G).

The mobile phase for the gradient elution consisted of two different mixtures of acetonitrile and diluted perchloric acid (HPLC water was adjusted to a pH 4 with diluted HClO_4). Mixture A: $\text{HClO}_4/\text{CH}_3\text{CN}$ (9:1 v/v), mixture B: $\text{HClO}_4/\text{CH}_3\text{CN}$ (4:6 v/v). The solvents were pre-mixed for two reasons. First degassing during the gradient mixing can be avoided, and secondly mobile phases with a minimum content of 10% acetonitrile are stable for a long time.

Standards

We obtained PT, PB, PR, CBZ, and ET from Desitin, Hamburg (F.R.G); PEMA, DM, and 5-ethyl-5-(p-tolyl)-barbituric acid (ETB) from Aldrich, Steinheim (F.R.G); EPO, DIOL, OXC, and OHC from Ciba-Geigy, Basle (Switzerland); MEPT and NIR from Sandoz, Nuernberg (F.R.G); ZA from Parke Davis & Co., Munich (F.R.G.).

The internal standard (ISTD) solution consisted of 15 mg ETB in 1000 ml ethyl acetate.

Calibration Samples

To 10-ml centrifuge tubes 0.5 ml calf serum and 50 μl from a stock solution containing 25 mg PEMA, 100 mg ET, 25 mg PR, 30 mg ZA, 5 mg DIOL, 50 mg PB, 50 mg DM, 5 mg

EPO, 25 mg PT, and 15 mg CBZ in 100 ml acetonitrile were added. The tubes were closed with screw caps and frozen at -18°C.

Extraction Procedure

To 10-ml centrifuge tubes 0.5 ml serum, 1.0 ml ISTD solution (pipetter/diluter), and 2.0 ml ethyl acetate were added. The tubes were closed with screw caps and mixed with a vortex-mixer for 10 min at 30°C. After centrifuging for 10 min, the supernatant fluid is transferred to clean tubes and evaporated to dryness (trace amounts of ethyl acetate can interfere with ZA in the chromatogram). The residue is dissolved in 100 ul methanol and 5 ul are injected.

Chromatographic Parameters

The flow was 0.3 ml/min, the column temperature was 65°C, the detection wavelength was 207 nm, and the injection volume was 1.5 µl.

The time program is as follows:

time [min]	0	0.5	9.5	10.0	12.0	15.0
	start	15%B	45%B	15%B	stop	end of run.

The chromatographic separation of 96 samples can be carried out in 24 hours by this gradient program (including the re-equilibration time).

C. RESULTS

The use of a microbore column for the analysis of AEDs in serum samples in our laboratory reduced the costs of solvents by 70%. This is because the flow rate was




FIGURE 1 Chromatogram of a test solution; RT: 2.40 Caffeine, 2.96 PEMA, 3.45 ET, 4.00 PR, 4.35 ZA, 5.06 DIOL, 5.40 ISTD used in [111,112], 6.01 NIR, 6.26 OHC, 6.57 PB, 7.20 DM, 7.96 EPO, 8.50 OXC, 8.89 MEPT, 9.57 ETB (ISTD), 10.79 PT, 11.34 CBZ.




FIGURE 2 Chromatogram of a serum from a patient on ZA, PR, and OXC medication; RT: 2.96 PEMA, 4.00 PR, 4.34 ZA, 5.06 DIOL, 6.26 OHC, 6.55 PB, 8.48 OXC, 9.51 ETB.

reduced from 1.0 to 0.3 ml/min. The price of the microbore column (which is 3-4 times higher than the price for a refill of our conventional column) was thus justified.

The use of a suitable in-line filter between the injector and the column is decisive for a long life of a microbore column. Without such a filter our first microbore column became unusable, due to blockage, after about 350 injections of sample extracts. If, however, exchangeable in-line filter discs with 0.5 μ m frits were used (see Materials) we could inject about 4,000 samples onto the microbore column without loss in resolution.

TABLE 2

Day-to-Day Precision of the Microbore Method measured by Control Sera with different Concentrations of AEDs

COS	AED	N	Xm	Range	S.D.	C.V. (%)
I	ET	31	70.17	\pm 4.45	2.20	3.14
	PR	31	11.24	\pm 0.35	0.19	1.70
	PB	31	28.43	\pm 1.25	0.48	1.68
	PT	31	13.88	\pm 0.75	0.29	2.11
	CBZ	31	5.51	\pm 0.25	0.11	1.92
II	ET	14	59.84	\pm 4.55	2.47	4.13
	PR	14	10.52	\pm 0.55	0.28	2.67
	PB	14	15.90	\pm 0.90	0.42	2.61
	PT	14	10.34	\pm 0.45	0.29	2.78
	CBZ	14	5.12	\pm 0.20	0.13	2.44
III	ET	14	155.31	\pm 8.75	5.32	3.43
	PR	14	26.10	\pm 0.85	0.46	1.76
	PB	14	45.35	\pm 1.20	0.77	1.69
	PT	14	49.99	\pm 1.65	1.13	2.26
	CBZ	14	15.21	\pm 0.35	0.24	1.56

COS = control serum, N = number of days, Xm = mean value of concentrations [μ g/ml], S.D. = standard deviation [μ g/ml], C.V.(%) = coefficient of variation expressed as a percentage.

The requirement for this was an exchange of the filter discs after 500-600 injections when the pressure increased over 200 bars.

The precision of the analysis made with microbore HPLC is, as can be seen from table 2, just as good as using conventional HPLC.

The larger coefficients of variation for ET, as opposed to those for the remaining AEDs are certainly not due to the separation by the microbore column, but obviously related to the evaporation step of the extraction method [104]. But, as shown by table 2, all coefficients of variation come within the "desirable limits" of 5% or less, defined by Szabo et al.[72].

ACKNOWLEDGEMENTS

The author is greatly indebted to Mr. G.S. Macpherson B.Sc., M.A., for translating the manuscript, to Dr. B. Rambeck and Dr. T. May for helpful discussions, and to Mrs. G. Kunert and Mrs. M. Berbuesse for technical assistance.

REFERENCES

1. Soldin S.E.; Anticonvulsants, in: Therapeutic drug monitoring and toxicology by liquid chromatography, Wong S.H.Y., Ed., Marcel Dekker, New York and Basel, 1985, p. 351.
2. Evans J.E.; Simultaneous measurement of diphenylhydantoin and phenobarbital in serum by high performance liquid chromatography. *Anal. Chem.* 45, 2428 (1973).
3. Albert K.S., Hallmark M.R., Carroll M.E., and Wagner J.G.; Quantitative separation of diphenylhydantoin and its parahydroxylated metabolites by high-performance liquid chromatography. *Res. Commun. Chem. Pathol. Pharmacol.* 6, 845 (1973).

4. Gauchel G., Gauchel F.D., and Birkofer L.; Eine Mikro-methode zur Bestimmung von Diphenylhydantoin (Phenhydan) im Blut durch Flüssigkeits-Chromatographie mit hohen Eingangsdrucken. *Z. Klin. Chem. Klin. Biochem.* 11, 35 (1973).
5. Gauchel G., Gauchel F.D., and Birkofer L.; A Micromethod for the determination of carbamazepine in blood by high speed liquid chromatography. *Z. Klin. Chem. Klin. Biochem.* 11, 459 (1973).
6. Eichelbaum M. and Bertilsson L.; Determination of carbamazepine and its epoxide metabolite in plasma by high-speed liquid chromatography. *J. Chromatogr.* 103, 135 (1975).
7. Atwell S.H., Green V.A., and Haney W.G.; Development and evaluation of method for simultaneous determination of phenobarbital and diphenylhydantoin in plasma by high-pressure liquid chromatography. *J. Pharm. Sci.* 64, 806 (1975).
8. Kitazawa S. and Komuro T.; High-speed liquid chromatographic determination of antiepileptic drugs in human plasma. *Clin. Chim. Acta* 73, 31 (1976).
9. Kabra P.M., Gotelli G., Stanfill R., and Marton L.J.; Simultaneous measurement of phenobarbital, diphenylhydantoin, and primidone in blood by high-pressure liquid chromatography. *Clin. Chem.* 22, 824 (1976).
10. Westenberg H.G. and de Zeeuw R.A.; Rapid and sensitive liquid chromatographic determination of carbamazepine suitable for use in monitoring multiple-drug anticonvulsant therapy. *J. Chromatogr.* 118, 217 (1976).
11. Maijub A.G., Stafford D.T., and Chamberlain R.T.; Anticonvulsant analyses by liquid chromatography. *Clin. Chem.*, 22, 1208 (1976).
12. Adams R.F. and Vandemark F.L.; Simultaneous high-pressure liquid-chromatographic determination of some anticonvulsants in serum. *Clin. Chem.* 22, 25 (1976).
13. Adams R.F. and Schmidt G.; Determination of less common anticonvulsants in serum using reversed-phase high-pressure liquid chromatography. *Chromatogr. Newsletter* 4, 8 (1976).
14. Soldin S.J. and Hill J.G.; Rapid micromethod for measuring anticonvulsant drugs in serum by high-performance liquid chromatography. *Clin. Chem.* 22, 856 (1976).
15. Kabra P.M. and Marton L.J.; Determination of carbamazepine in blood or plasma by high-pressure liquid chromatography. *Clin. Chem.* 22, 1070 (1976).

16. Soldin S.J. and Hill J.G.; Interference with column-chromatographic measurement of primidone. *Clin. Chem.* 23, 782 (1977).
17. Soldin S.J. and Hill J.G.; Routine dual-wavelength analysis of anticonvulsant drugs by high-performance liquid chromatography. *Clin. Chem.* 23, 2352 (1977).
18. Kabra P.M., Stafford B.E., and Marton L.J.; Simultaneous measurement of phenobarbital, phenytoin, primidone, ethosuximide, and carbamazepine in serum by high-pressure liquid chromatography. *Clin. Chem.* 23, 1284 (1977).
19. Adams R.F., Schmidt G.J., and Vandemark F.L.; A micro method for the determination of carbamazepine and the 10,11-epoxide metabolite in serum and urine by reverse-phase liquid chromatography. *Chromatogr. Newsletter* 5, 11 (1977).
20. Mihaly G.W., Phillips J.A., Louis W.J., and Vajda F.J.; Measurement of carbamazepine and its epoxide metabolite by high-performance liquid chromatography, and a comparison of assay techniques for the analysis of carbamazepine. *Clin. Chem.* 23, 2283 (1977).
21. Gaetani E., Laureri C.F. Prati G., and Zambelloni G.; Chromatografia liquido liquido ad alta pressione. Dosaggio di antiepilettici nel plasma. *Il Farmaco*, Ed. Pr. 33, 136 (1978).
22. Schmidt G.J.; Evaluation of new internal standards for the analysis of carbamazepine and procainamide by liquid chromatography. *Chromatogr. Newsletter* 6, 37 (1978).
23. Hackett L.P. and Dusci L.J., High performance liquid chromatography in clinical toxicology. *Clin. Toxicol.* 13, 551 (1978).
24. Gonnet C., Porthault M., Bory C., and Baltassat P.; Microdosages du phenobarbital et de l'acide valproique dans les millieux biologiques par chromatographie en phase liquide. *Analisis* 6, 406 (1978).
25. Farinotti R., Pfaff M.C., and Mahuzier G.; Dosage simultane du phenobarbital et de l'acide valproique dans le plasma par chromatographie liquide haute performance. *Ann. Biol. Clin.* 36, 347 (1978).
26. Kabra P.M., McDonald D.M., and Marton L.J.; A simultaneous high-performance liquid chromatographic analysis of the most common anticonvulsants and their metabolites in the serum. *J. Anal. Toxicol.* 2, 127 (1978).
27. Adams R.F., Schmidt G.J., and Vandemark F.L.; A micro liquid column chromatography procedure for twelve anticonvulsants and some of their metabolites. *J. Chromatogr.* 145, 275 (1978).

28. Helmsing P.J., van der Woude J., and van Eupen O.M.; A micromethod for simultaneous estimation of blood levels of some commonly used antiepileptic drugs. *Clin. Chim. Acta* 89, 301 (1978).
29. Kabra P.M., Koo H.Y., and Marton L.J.; Simultaneous liquid-chromatographic determination of 12 common sedatives and hypnotics in serum. *Clin. Chem.* 24, 657 (1978).
30. Slonek J.E., Peng G.W., and Chiou W.L.; Rapid and micro high-pressure liquid chromatographic determination of plasma phenytoin levels. *J. Pharm. Sci.* 67, 1462 (1978).
31. Gupta R.N., Keane P.M., and Gupta M.L.; Valproic acid in plasma, as determined by liquid chromatography. *Clin. Chem.* 25, 1984 (1979).
32. Sutheimer C., Fretthold D., and Sunshine I.; The determination of valproic acid in plasma using reversed-phase liquid chromatography. *Chromatogr. Newsletter* 7, 1 (1979).
33. Johnston C.K. and Lester G.H.; A simple procedure for the determination of carbamazepin in plasma by high pressure-liquid chromatography. *Ann. Clin. Biochem.* 16, 213 (1979).
34. Astier A. and Plat M.M.; Micro determination simultanee de la carbamazepine plasmatique et de son metabolite 10,11-epoxy par chromatographie liquide haute performance. Application a la pharmacocinetique de l epoxy-10,11 carbamazepine. *Lyon Medical* 242, 551 (1979).
35. Freeman D.J. and Rawal N.; Serum anticonvulsant monitoring by liquid chromatography with a methanolic mobile phase. *Clin. Chem.* 25, 810 (1979).
36. Pesh-Imam M., Fretthold D.W., Sunshine I., Kumar S., Terrentine S., and Willis C.E.; High pressure liquid chromatography for simultaneous analysis of anticonvulsants: Comparison with EMIT system. *Ther. Drug Monit.* 1, 289 (1979).
37. Astier A., Maury M., and Barbizet J.; Simultaneous, rapid high-performance liquid chromatographic microanalysis of plasma carbamazepine and its 10,11-epoxide metabolite. Applications to pharmacokinetic studies in humans. *J. Chromatogr.* 164, 235 (1979).
38. Farinotti R. and Mahuzier G.; Simultaneous determination of six anticonvulsants in serum by high performance liquid chromatography. *J. Liquid Chromatogr.* 2, 345 (1979).
39. Mahuzier G., Farinotti R., and Pfaff-Dessalles M.C.; Application de la chromatographie en phase liquide a la determination simultanee des anticonvulsivants dans le plasma. *Analisis* 7, 360 (1979).

40. Hodnett C.N. and Eberhardt R.D.; Optimization of the determination of drugs by high-pressure liquid chromatography (HPLC). *J. Anal. Toxicol.* 3, 187 (1979).
41. Williams R.C. and Viola J.L.; Application of an automated extractor/concentrator to the analysis of anticonvulsant drugs in blood serum by high-performance liquid chromatography. *J. Chromatogr.* 185, 505 (1979).
42. Perchalski R.J., Bruni J., Wilder B.J., and Willmore L.J.; Simultaneous determination of the anticonvulsants, cinromide (3-bromo-N-ethylcinnamamide), 3-bromocinnamamide, and carbamazepine in plasma by high-performance liquid chromatography. *J. Chromatogr.* 163, 187 (1979).
43. Draper P., Shapcott D., and Lemieux B.; Single column high pressure liquid chromatographic determination of drugs in blood. *Clin. Biochem.* 12, 52 (1979).
44. Bernardo M.; Improved sample preparation for measuring anticonvulsant drugs in serum by "high-performance" liquid chromatography. *Clin. Chem.* 25, 1861 (1979).
45. Mathies J.C. and Austin M.A.; Modified acetonitrile protein-precipitation method of sample preparation for drug assay by liquid chromatography. *Clin. Chem.* 26, 1760 (1980).
46. Stafford B.E., Kabra P.M., and Marton L.J.; Some comments on anticonvulsant-drug monitoring by liquid chromatography. *Clin. Chem.* 26, 1366 (1980).
47. Soldin S.J.; High performance liquid chromatographic analysis of anti-convulsant drugs using radial compression columns. *Clin. Biochem.* 13, 99 (1980).
48. Rydzewski R.S., Gadsden R.H., and Phelps C.A.; Simultaneous rapid HPLC determination of anticonvulsant drugs in plasma and correlation with EMIT. *Ann. Clin. Lab. Sci.* 10, 89 (1980).
49. Couri D., del Villar C.S., and Toy-Manning P.; Simultaneous quantitative assay of phenobarbital, phenytoin, and p-hydroxydiphenylhydantoin by HPLC and a comparison with EMIT(R). *J. Anal. Toxicol.* 4, 227 (1980).
50. Sawchuk R.J. and Cartier L.L.; Liquid-chromatographic method for simultaneous determination of phenytoin and 5-(4-hydroxyphenyl)-5-phenylhydantoin in plasma and urine. *Clin. Chem.* 26, 835 (1980).
51. Kraak J.C., Smedes F., and Meijer J.W.A.; Application of on-column concentration of deproteinized serum to the HPLC determination of anticonvulsants. *Chromatographia* 13, 673 (1980).

52. Dolan J.W., van der Wal S., Bannister S.J., and Snyder L.R.; On-line liquid-chromatographic analysis for drugs in serum with the technicon "FAST-LC" system: Performance data to theophylline and for four commonly used anticonvulsants and their metabolites. *Clin. Chem.* 26, 871 (1980).
53. Christofides J.A. and Fry D.E.; Measurement of anticonvulsants in serum by reversed-phase ion-pair liquid chromatography. *Clin. Chem.* 26, 499 (1980).
54. Chu S.Y., Oliveras L., and Deyasi S.; Extraction procedure for measuring anticonvulsant drugs by liquid chromatography. *Clin. Chem.* 26, 521 (1980).
55. MacKichan J.J.; Simultaneous liquid chromatographic analysis for carbamazepine and carbamazepine 10,11-epoxide in plasma and saliva by use of double internal standardization. *J. Chromatogr.* 181, 373 (1980).
56. Alric R., Cociglio M., Blayac J.P., and Puech R.; Performance evaluation of a reversed-phase, high-performance liquid chromatographic assay of valproic acid involving a "solvent demixing" extraction procedure and precolumn derivatisation. *J. Chromatogr.* 224, 289 (1981).
57. Schmit J.M., Rigaut P., Daldoss C., Renaudeau C., and Meunier J.; Interet des dosages plasmatiques des médicaments anticonvulsants. *Feuillets Biol.* 22, 115 (1981).
58. Cisse H., Farinotti R., Kirkiacharian S., and Dauphin A.; Dosage de l'acide dipropylacétique dans le plasma par chromatographie en phase liquide et détection spectrofluorimétrique. *J. Chromatogr.* 225, 509 (1981).
59. Soldin S.J. and Walter M.; Improved HPLC analysis for anticonvulsant drugs employing radial compression columns. *Clin. Biochem.* 14, 161 (1981).
60. Schmit J.M., Cloitre B., Rigaut P., Aucouturier P., and Meunier J.; Détermination du phénobarbital, de la phénytoïne et de la carbamazépine plasmatiques par chromatographie en phase liquide. *Analisis* 9, 70 (1981).
61. Quattrone A.J. and Putnam R.S.; A single liquid-chromatographic procedure for therapeutic monitoring of theophylline, acetaminophen, or ethosuximide. *Clin. Chem.* 27, 129 (1981).
62. Salvesen B. and Lyngbakken E.; Assay of common anticonvulsant drugs simultaneously present in human sera by HPLC compared to GLC. *Medd. Norsk Farm. Selsk.* 43, 45 (1981).
63. Furlanut M., Delucca M.G., Dilberis G., and Barnaba A.; Rapid and sensitive high-pressure liquid chromatographic method for monitoring carbamazepine levels in serum. *Br. J. Clin. Pharmacol.* 11, 393 (1981).

64. Dungan S.M., Powers N.E., Klienman N., and Scheeler P.L.; Anticonvulsant analysis by liquid chromatography: Reverse-phase u-Bondapack C-18 and Radial Pak A systems compared. *J. Chromatogr. Sci.* 18, 23 (1981).
65. Conlan A.M., Tabor K.J., and Lesko L.J.; Liquid chromatography of anticonvulsants in an inappropriately drawn (lipemic) serum sample. *Clin. Chem.* 27, 513 (1981).
66. George R.C.; Improved sample treatment before liquid-chromatographic determination of anticonvulsants in serum. *Clin. Chem.* 27, 198 (1981).
67. Rambeck B., Riedmann M., and Meijer J.W.A.; Systematic method development in liquid chromatography applied to the determination of antiepileptic drugs. *Ther. Drug Monit.* 3, 377 (1981).
68. Riedmann M., Rambeck B., and Meijer J.W.A.; Quantitative simultaneous determination of eight common antiepileptic drugs and metabolites by liquid chromatography. *Ther. Drug Monit.* 3, 397 (1981).
69. Kinberger B., Wahrgren P., and Holmen A.; Determination of ethosuximide, phenobarbital, carbamazepine, carbamazepine epoxide and phenytoin in serum by high-performance liquid chromatography using radially compressed columns and an aqueous methanolic mobile phase. *Anal. Letters* 14, 1419 (1981).
70. Ehrental W. and Rochel M.; Kontrolle der Valproinsäure-Therapie durch Serumspiegelbestimmungen mit HPLC oder EMIT und durch gleichzeitige Bestimmung klinisch-chemischer Parameter. *Arzneim.-Forsch./Drug Res.* 32, 449 (1982).
71. Kline W.F., Enagonio D.P., Reeder D.J., and May W.E.; Liquid chromatographic determination of valproic acid in human serum. *J. Liquid Chromatogr.* 5, 1697 (1982).
72. Szabo G.K. and Browne T.R.; Improved isocratic liquid-chromatographic simultaneous measurement of phenytoin, phenobarbital, primidone, carbamazepine, ethosuximide, and N-desmethylethosuximide in serum. *Clin. Chem.* 28, 100 (1982).
73. Kinberger B. and Holmen A.; Analysis for carbamazepine and phenytoin in serum with a high speed liquid chromatography system (Perkin-Elmer). *Clin. Chem.* 28, 718 (1982).
74. Sawchuk R.J. and Cartier L.L.; Simultaneous liquid-chromatographic determination of carbamazepine and its epoxide metabolite in plasma. *Clin. Chem.* 28, 2127 (1982).
75. Elyas A.A., Ratnaraj N., Goldberg V.D., and Lascelles P.T.; Routine monitoring of carbamazepine and carbamazepine-

- 10,11-epoxide in plasma by high-performance liquid chromatography using 10-methoxy carbamazepine as internal standard. *J. Chromatogr.* 231, 93 (1982).
76. Moody J.P. and Allan S.M.; Measurement of valproic acid in serum as the 4-bromophenacyl ester by high-performance liquid chromatography. *Clin. Chim. Acta* 127, 263 (1983).
77. Riegenmann H.J. and Juergens U.; HPLC-Analyse von Antiepileptika mit Säulenschalttechnik. *LaborPraxis* 3, March (1983).
78. Haroon Y. and Keith D.A.; High-performance liquid chromatography of anticonvulsants - micro-assay for phenytoin and phenobarbital. *J. Chromatogr.* 276, 445 (1983).
79. Neels H.M., Totte J.A., Verkerk R.M., Vlietinck A.J., and Scharpe S.L.; Simultaneous high performance liquid-chromatographic determination of carbamazepine, carbamazepine-10,11-epoxide, ethosuximide, phenobarbital, phenytoin, primidone and phenylethylmalonamide in plasma. *J. Clin. Chem. Clin. Biochem.* 21, 295 (1983).
80. Greenblatt D.J., Matlis R., and Abernethy D.R.; Improved liquid chromatographic analysis of phenytoin and salicylate using radial compression separation. *J. Chromatogr.* 275, 450 (1983).
81. Turnell D.C., Trevor S.C., and Cooper J.D.H.; A rapid procedure for the simultaneous estimation of the anticonvulsant drugs, ethosuximide, phenobarbitone, phenytoin, and carbamazepine in serum using high-pressure liquid chromatography. *Ann. Clin. Biochem.* 20, 37 (1983).
82. Kabra P.M., Nelson M.A., and Marton L.J.; Simultaneous very fast liquid-chromatographic analysis of ethosuximide, primidone, phenobarbital, phenytoin, and carbamazepine in serum. *Clin. Chem.* 29, 473 (1983).
83. Kushida K., Chiba K., and Ishizaki T.; Simultaneous liquid chromatographic determination of chloramphenicol and anti-epileptic drugs (phenobarbital, phenytoin, carbamazepine, and primidone) in plasma. *Ther. Drug Monit.* 5, 127 (1983).
84. Stout S.A. and DeVane C.L.; Tissue assay of phenobarbital, phenytoin and p-hydroxyphenytoin by high-performance liquid chromatography. *J. Chromatogr.* 285, 500 (1984).
85. Nakamura M., Kondo K., Nishioka R., and Kawai S.; Improved procedure for the high-performance liquid chromatographic determination of valproic acid in serum as its phenacylester. *J. Chromatogr.* 310, 450 (1984).
86. Chan E.M. and Chan S.C.; Screening for acidic and neutral drugs by high performance liquid chromatography in post-mortem blood. *J. Anal. Toxicol.* 8, 173 (1984).

87. Ou C.N. and Rognerud C.L.; Simultaneous measurement of ethosuximide, primidone, phenobarbital, phenytoin, carbamazepine, and their bioactive metabolites by liquid chromatography. *Clin. Chem.* 30, 1667 (1984).
88. Kumps A.; Simultaneous HPLC determination of oxcarbazepine, carbamazepine and their metabolites in serum. *J. Liquid Chromatogr.* 7, 1235 (1984).
89. Juergens U.; Routine determination of eight common anti-epileptic drugs and metabolites by high-performance liquid chromatography using a column-switching system for direct injection of serum samples. *J. Chromatogr.* 310, 97 (1984).
90. Nazareth A., Jaramillo L., Karger B.L., Giese R.W., and Snyder L.R.; Automated analysis of antiepileptic drugs in serum by column-switching high-performance liquid chromatography. *J. Chromatogr.* 309, 357 (1984).
91. Kuhnz W. and Nau H.; Automated high-pressure liquid chromatographic assay for antiepileptic drugs and their major metabolites by direct injection in serum samples. *Ther. Drug Monit.* 6, 478 (1984).
92. Bistue C., Jarry C., and Brachet-Liermain A.; Extraction automatique et dosage par chromatographie liquide haute performance des medicaments anti-epileptiques. *Ann. Pharm. Francaises* 42, 569 (1984).
93. Chan K., Lok S., and Teoh R.; The simultaneous determination of five anti-epileptic drugs in plasma by high performance liquid chromatography. *Meth. and Find. Exptl. Clin. Pharmacol.* 6, 701 (1984).
94. Grasela D.M. and Rocci M.L.; Liquid chromatographic micro-assay for carbamazepine and its 10,11-epoxide in plasma. *J. Pharm. Sci.* 73, 1874 (1984).
95. Cornelis J. and Chaillet F.; Determination simultanee par chromatographie liquide haute performance de huit antiepileptiques et sedatifs dans le plasma. *Ann. Biol. Clin.* 42, 295 (1984).
96. Soto-Otero R. and Sierra-Marcuno G.; Improved simultaneous liquid-chromatographic determination of antiepileptic drugs in plasma. *Clin. Chem.* 30, 817 (1984).
97. Wad N.; Simultaneous determination of eleven antiepileptic compounds in serum by high-performance liquid chromatography. *J. Chromatogr.* 305, 127 (1984).
98. Gerson B., Bell F., Chan S., Broussard L.A., Stearns F.M., Dalrymple R., and Frings C.S.; Antiepileptic agents - primidone, phenobarbital, phenytoin, and carbamazepine by reversed-phase liquid chromatography. *Clin. Chem.* 30, 105 (1984).

99. Nicot G., Lachatre G., Valette J.P., Merle L., and Nouaille Y.; Dosage plasmatique du phenobarbital, pentobarbital et pentiobarbital par chromatographie liquide a haute performance. *Therapie* 39, 361 (1984).
100. Chan, K.; Simultaneous determination of carbamazepine and its epoxide metabolite in plasma and urine by high-performance liquid chromatography. *J. Chromatogr.* 342, 341 (1985).
101. Willems H.J.J., van der Horst A., de Goede P.N.F.C., and Haakmeester G.J.; Determination of some anticonvulsants, antiarrhythmics, benzodiazepines, xanthines, paracetamol and chloramphenicol by reversed phase HPLC. *Pharm. Weekblad Sci. Ed.* 7, 150 (1985).
102. Soto-Otero R., Mendez-Alvarez E., and Sierra-Marcuno G.; High performance liquid chromatographic procedure for the simultaneous determination of theophylline, caffeine, and phenobarbital in neonates. *J. Clin. Chem. Clin. Biochem.* 23, 303 (1985).
103. Kushida K. and Ishizaki T.; Concurrent determination of valproic acid with other antiepileptic drugs by high-performance liquid chromatography. *J. Chromatogr.* 338, 131 (1985).
104. Wad N.; Rapid extraction method for ethosuximide and other antiepileptics in serum for determination by high-performance liquid chromatography. *J. Chromatogr.* 338, 460 (1985).
105. Kumps A., Genin-Ramakers J., and Mardens Y.; Simultaneous determination of anticonvulsant drugs and metabolites in plasma by high-performance liquid chromatography. *J. Chromatogr.* 342, 469 (1985).
106. Rambeck B.; Pharmacological interactions of mesuximide with phenobarbital and phenytoin in hospitalized epileptic patients. *Epilepsia* 20, 147 (1979).
107. Dijkhuis I. and Vervloet E.; Rapid determination of the antiepileptic drug di-n-propylacetic acid in serum. *Pharm. Weekblad* 109, 42 (1974).
108. Meijer J.W.A.; Report on Worksheets collected after WODA-DIBOF I (Workshop on the determination of anti-epileptic drugs in body fluids), in: *Clinical pharmacology of anti-epileptic drugs*, Schneider H., Janz D., Gardner-Thorpe C., Meinardi H. and Shewin A.L., Eds., Springer-Verlag, Berlin/Heidelberg/New York, 1975, p. 286.
109. Juergens U., May T., Hillenkoetter K., and Rambeck B.; Systematic comparison of three basic methods of sample pretreatment for high-performance liquid chromatographic analysis of antiepileptic drugs using gas chromatography as a reference method. *Ther. Drug Monit.* 6, 334 (1984).

110. Roth W., Beschke K., Jauch R., Zimmer A., and Koss W.; Fully automated high-performance liquid chromatography - A new chromatograph for pharmacokinetic drug monitoring by direct injection of body fluids. *J. Chromatogr.* 222, 13 (1981).
111. Ito T., Yamaguchi T., Miyazaki H., Sekine Y., Shimizu M., Ishida S., Yagi K., Kakegawa N., Seino M., and Wada T.; Pharmacokinetic studies of AD-810, a new antiepileptic compound - Phase I trials. *Arzneim.-Forsch./Drug Res.* 32, 1581 (1982).
112. Wagner J.G., Sackellares J.C., Donofrio P.D., Berent S., and Sakmar E.; Nonlinear pharmacokinetics of CI-912 in adult epileptic patients. *Ther. Drug Monit.* 6, 277 (1984).
113. Theisohn M. and Heimann G.; Disposition of the anti-epileptic oxcarbazepine and its metabolites in healthy volunteers. *Eur. J. Clin. Pharmacol.* 22, 545 (1982).
114. Menge G. and Dubois J.P.; Determination of oxcarbazepine in human plasma by high-performance liquid chromatography. *J. Chromatogr.* 275, 189 (1983).
115. Noirfalise A. and Collinge A.; Quantitative determination of oxcarbazepine. *J. Chromatogr.* 274, 417 (1983).
116. Kuepfer A., James R., Carr K., and Branch R.; Analysis of hydroxylated and demethylated metabolites of mephenytoin in man and laboratory animals using gas-liquid chromatography and high-performance liquid chromatography. *J. Chromatogr.* 232, 93 (1982).
117. Juergens U.; Simultaneous determination of zonisamide (CI-912) and nine other antiepileptic drugs and metabolites in serum by high-performance liquid chromatography. Poster on the 16th Epilepsy International Congress, Hamburg, September 1985.